ACR246, a first in next-generation 5T4-ADC, as a potential choice of treating 5T4-positive solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

LONDON - Biotechnology company Amprologix has raised £740,000 in a pre-Series A funding round to accelerate the development of novel antibiotics targeting antimicrobial-resistant diseases, according ...

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2025 / Sea Pharmaceuticals, LLC (Sea) today announced its selection of Inotiv Inc. (NASDAQ:NOTV) for pre-clinical development IND-enabling studies to support ...

Apitope, a drug discovery and development company focused on disease-modifying peptide treatments for the underlying cause of autoimmune and allergic diseases, announced that its peptide therapy for ...

Ra’anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Capture & ...

- Single-step CD45-engager technology shows robust immune evasion with functional persistence in pre-clinical models - Phase 1 study to evaluate ‘off-the-shelf’ natural killer cell cancer ...

Empowering MedTech SMEs with flexible, realistic and cost-effective pre-clinical testing, validation and demo space at Heriot-Watt University’s Immersive Suite.